ConvaTec Group’s (CTEC) Overweight Rating Reiterated at JPMorgan Chase & Co.

JPMorgan Chase & Co. reaffirmed their overweight rating on shares of ConvaTec Group (LON:CTEC) in a report released on Wednesday, MarketBeat.com reports. They currently have a GBX 307 ($4.14) price target on the stock.

Separately, Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a GBX 315 ($4.25) price objective on shares of ConvaTec Group in a research report on Thursday, July 3rd.

ConvaTec Group Price Performance

Shares of CTEC stock opened at GBX 260.80 ($3.52) on Wednesday. ConvaTec Group has a twelve month low of GBX 211.80 ($2.86) and a twelve month high of GBX 311.20 ($4.20). The company has a current ratio of 2.26, a quick ratio of 0.96 and a debt-to-equity ratio of 85.32. The company has a market capitalization of £6.63 billion, a PE ratio of 43.92, a price-to-earnings-growth ratio of 0.93 and a beta of 0.64. The firm has a fifty day simple moving average of GBX 278.14 and a 200-day simple moving average of GBX 257.18.

ConvaTec Group Company Profile

ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns.